CENTRO DI DOCUMENTAZIONE SUI DISPOSITIVI MEDICI

From Web site Written by  Catharine Paddock PhD Published:  Thursday 19 January 2017 Scientists have developed a dental implant containing a reservoir for the slow release of drugs. Laboratory tests in which the reservoir slowly released a strong antimicrobial agent showed that the new implant can prevent and eliminate bacterial biofilms - a major cause of infection associated with dental implants. The researchers, from various departments at KU Leuven in Belgium, describe how they designed and tested the implant in a paper published in the journal   European Cells & Materials . Lead author Dr. Kaat De Cremer, from the Centre of Microbial and Plant Genetics at KU Leuven, explains that the reservoir in the implant can be filled by removing the cover screw.  She adds that: "The implant is made of a porous composite material, so that the drugs gradually diffuse from the reservoir to the outside of the implant, which is in direct contact wi...

Luca Martinelli Publication 25th November 2016 1.FOREWORD It’s appropriate to underline that as of today (25.11.2016) the Official Journal has not published yet the new regulation. This fact doesn’t prevent to make some considerations about some new features in the final draft. The new Regulation of the European Parliament of the Council on medical devices, amending Directive 2001/83/CE, Regulation (CE) nr. 178/2002 and Regulation (CE) nr. 1223/2009 will replace Directives 90/385/CEE “on the approximation of the States member relating the active implantable medical devices” and 93/42/CEE “on medical devices”, establishes the figure of the “ person responsible for regulatory compliance ”. 2.PERSON RESPONSIBLE FOR REGULATORY COMPLIANCE 2.1 Who is him? The new Regulation requires that the manufacturer must ensure that the supervision and control of medical devices manufacturing, as well as the supervisory and post-market surveillance activities related to them, ...

Quasar Dental Equipment presenta GREENBRUSH , il nuovo strumento da laboratorio per modellazione. Quasar Dental Equipment presents GREENBRUSH , the new carver laboratory instrument. GREENBRUSH è composto da un manico in resina atossica e acciaio INOX sul quale si possono applicare a proprio piacimento una delle sei punte più utilizzate per la modellazione di ceramica, composito ecc. insieme a un pennellino monouso. GREENBRUSH is made with an atoxic resin handle and stanley Steel where you can put one of the six tips used for carving ceramic, composite and so on, together with a disposable brush.                    GREENBRUSH GREENBRUSH si aggiunge al già noto REDTIP strumento per modellazione che permette di inserire le punte su entrambi i lati. GREENBRUSH is added to REDTIP already known instrument for carving which permits to insert the tips on both sides.  REDTIP

L'impiego in campo medico-chirurgico dei Google glass è già noto ma l a prima applicazione al mondo per il settore dentistico per i Google glass è nata in Italia. I Google glass per dentisti si chiamano  “Dental Class”. Gherò, noto distributore e fabbricante OBL italiano di dispositivi medici per odontoiatria, e Sell Well, agenzia italiana di marketing che si occupa di strategie di di consulting, conception, creativity, communication e controlling, hanno sviluppato il primo software per dentisti aplicato ai Google Glass. Grazie a questa applicazione il dentista potrà ottimizzare i tempi e migliorare le prestazioni sul paziente avendo continuamente a disposizioni le informazioni su di esso. Le nuove informazioni acquisite sul paziente possono essere digitalizzate in tempo reale. I Dental Class si indossano durante il lavoro sul paziente. Il minicomputer, posizionato sulla stanghetta destra dei Google Glass, si collega direttamente al software sul pc dello...

From Website Posted 32 January 2017 By  Zachary Brennan "In a sign of what’s to come for the US Food and Drug Administration (FDA), President Donald Trump told pharmaceutical company CEOs Tuesday that his administration will be “cutting regulations at a level no one has ever seen before.” The comments, which came before the meeting with CEOs from industry group PhRMA, Merck, Novartis, Johnson & Johnson, Celgene and others, Trump said in terms of the drug approval process: “We’re also going to be streamlining the process, so that from your standpoint, when you have a drug you can actually get it approved, instead of waiting for many, many years." He also called for significantly lower drug prices and  again  for better negotiations on drug prices between Medicare and companies. “We’re going to get the approval process much faster,” he repeated, noting that “one thing that’s always disturbed me is that you come up with a new drug for a pa...